Instinct Bio Completes SPAC Merger, Nasdaq Debut Set for July 24 at $288M Valuation
ACQC has more than doubled off its 52-week low of $2 on light trading volume (0.1× avg).
Summary
Instinct Bio completed its business combination with Relativity Acquisition Corp. and will begin trading on Nasdaq under ticker BIOT on July 24, 2026. The deal values the combined company at a pro forma enterprise value of approximately $288 million. This marks the culmination of a SPAC merger that was previously approved by shareholders, as disclosed in recent SEC filings. The listing provides Instinct Bio with a public currency to scale its regenerative medicine and longevity platform, which already generates revenue. The debut comes amid a challenging IPO market, making the successful completion a notable milestone. The company's pipeline and commercial footprint in Asia offer a differentiated play on the growing longevity market.
At the time of this announcement, ACQC was trading at $16.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $68.9M. The 52-week trading range was $2.00 to $35.22. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.